Asuragen Armored RNA Quant SARS-CoV-2 Control

Asuragen is offering an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic. The new control material targets the SARS-CoV-2 viral nucleocapsid region and, along with the company's new RNAse P construct, aligns with the US Centers for Disease Control and Prevention- and World Health Organization-recommended diagnostic panel. Asuragen said that armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.